It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
Stanley Joewono is an Indonesia social media influencer and exercise enthusiast. Diagnosed with thalassemia at just 8 months ...
ELK GROVE VILLAGE, Ill., Nov. 14, 2024 /PRNewswire/ -- Orsini has been chosen by Vertex Pharmaceuticals Incorporated to ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
Limitations of Use Following treatment with LYFGENIA, patients with α-thalassemia trait (-α3.7/-α3.7) may experience anemia with erythroid dysplasia that may require chronic red blood cell ...
RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...
Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...
Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...
CASGEVYâ„¢ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...
The $2.2 million therapy has come a long way since its groundbreaking sickle cell disease FDA approval in December and subsequent January nod in beta thalassemia. As Vertex looks to tap into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback